PharmaTimes5d
NICE recommends remote monitoring technology for heart failure patients
The National Institute for Health and Care Excellence (NICE) has announced that people with heart failure can now stay healthier remotely through advanced remote monitoring technology designed to ...
PharmaTimes5d
UK dementia clinical trial participation set to boost by ‘tens of thousands’
The new Dementia Trials Accelerator is set to receive £20m of government funding The Dementia Trials Accelerator, led by the UK Dementia Research Institute and Health Data Research UK and funded by ...
PharmaTimes6d
WHO report highlights resurgence of tuberculosis
The World Health Organization’s (WHO) newly published report has placed tuberculosis (TB) as the leading infectious disease killer in 2023, surpassing COVID-19. Newly identified TB cases climbed to ...
PharmaTimes11d
Diabetes dichotomy
Make no mistake, innovation in diabetes care is critical. Diabetes never takes a break. People with diabetes manage their condition on their own, 365 days a year – making multiple therapy decisions ...
PharmaTimes11d
Chosen path
The Medicines and Healthcare products Regulatory Agency (MHRA) has granted approval of lecanemab. This particular therapy is a monoclonal antibody treatment for use among patient populations with mild ...
PharmaTimes11d
Super models
The impact of AI/data-driven drug discovery is evolving rapidly in life sciences. Harnessing the beneficial potential of this technology, however, requires its ...
PharmaTimes12d
NICE recommendation for new Alexion PNH treatment
Alexion, AstraZeneca Rare Disease, announced that the National Institute for Health and Care Excellence (NICE) has given a positive recommendation for Voydeya (danicopan). This first-in-class, oral ...
PharmaTimes12d
Laura Vergani
Chiesi Group has appointed Laura Vergani as SVP of Global Communications Chiesi Group has announced that Laura Vergani has joined as Senior Vice President of Global Communications & Public Affairs.
PharmaTimes12d
Darzalex subcutaneous regimen approved by European Commission
The European Commission has approved the subcutaneous (SC) formulation of DARZALEX (daratumumab) in combination with ...
PharmaTimes13d
Calluna Pharma completes successful phase 1 trial of new fibrotic disease drug
Calluna Pharma AS has announced the successful completion of Phase 1 clinical trials for its lead drug candidate, CAL101, a first-in-class monoclonal antibody (mAb) targeting fibrotic and ...
PharmaTimes15d
NICE recommends Santen’s Roclanda to treat glaucoma and ocular hypertension
Primary open-angle glaucoma affects around 2% of adults aged 40 years and older in the UK The National Institute for Health and Care Excellence (NICE) has issued guidance recommending Santen’s ...